1. Rapid and Accurate Diagnosis of the Respiratory Disease Pertussis on a Point-of-Care Biochip
- Author
-
Delfina C. Dominguez, Maowei Dou, Jennifer Dien Bard, Feng Shen, Xiujun Li, and Natalie Macias
- Subjects
Bordetella pertussis ,Bacterial lysis ,Loop-mediated isothermal amplification (LAMP) ,Loop-mediated isothermal amplification ,Point-of-care detection ,01 natural sciences ,03 medical and health sciences ,0302 clinical medicine ,medicine ,030212 general & internal medicine ,0101 mathematics ,Biochip ,Whooping cough ,Point of care ,Microfluidic biochip ,lcsh:R5-920 ,biology ,business.industry ,010102 general mathematics ,Respiratory disease ,General Medicine ,medicine.disease ,biology.organism_classification ,Virology ,DNA extraction ,3. Good health ,lcsh:Medicine (General) ,business ,Research Paper ,Pertussis diagnosis - Abstract
Background: Pertussis is a highly contagious respiratory disease caused by the bacterium Bordetella pertussis (B. pertussis). The infection is difficult to diagnose especially in underserved or resource-limited areas. We developed a low-cost and instrument-free diagnostic method for rapid and accurate detection of B. pertussis on a point-of-care (POC) testing device. Methods: We developed a paper/polymer hybrid microfluidic biochip integrated with loop-mediated isothermal amplification (LAMP) method for the rapid and accurate detection of B. pertussis. This microfluidic approach was validated by testing 100 de-identified remnant clinical nasopharyngeal swabs and aspirates, which were confirmed to be either positive or negative for B. pertussis by a validated real-time PCR assay at the Children's Hospital Los Angeles. Findings: The instrument-free detection results could be successfully read by the naked eye within 45 min with a limit of detection (LOD) of 5 DNA copies per well. Our optimized bacterial lysis protocol allowed the direct testing of clinical samples without any complicated sample processing/preparation (i.e. DNA extraction) or the use of any equipment (e.g. centrifuges). The validation of the microfluidic approach was accomplished by testing 100 clinical samples. High sensitivity (100%) and specificity (96%) with respect to real-time PCR were achieved. Interpretation: This microfluidic biochip shows great potential for point-of-care disease diagnosis in various venues including schools and physician's offices, especially in low-resource settings in developing nations. Funding: NIH/NIAID under award number R21AI107415, NIH RCMI Pilot Grant, the Philadelphia Foundation, the Medical Center of the Americas Foundation. Keywords: Pertussis diagnosis, Point-of-care detection, Microfluidic biochip, Whooping cough, Loop-mediated isothermal amplification (LAMP)
- Published
- 2019